Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040677 · ClinicalTrials.gov registry record · Phase 2

A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.

A Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Icagen.

Completed
Registry status
Phase 2
Development phase
90
Enrollment target
19
Study locations

NCT00040677: Completed Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Icagen.

NCT00040677 is a Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Icagen. The registered enrollment target is 90 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower). The trial reports 19 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040677, a Phase 2 study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Icagen.

COMPLETED
Registry status
Phase 2
Development phase
90 participants
Enrollment target
19
Study locations

Study Summary

ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and thus should prevent or delay the sickling process. By reducing sickled cells, an improvement in anemia, a reduction in painful crises, and ultimately, less end-organ disease is anticipated.

Conditions Studied

Sickle Cell Disease Sickle Cell Anemia

Interventions

  • DRUG Placebo
  • DRUG Low Dose ICA-17043
  • DRUG High dose ICA-17043

Study Locations (19)

California

  • Study Site - Oakland
  • Study Site - San Francisco

New York

  • Study Site - Brooklyn
  • Study Site - New York

North Carolina

  • Study Site - Chapel Hill
  • Study Site - Durham

Pennsylvania

  • Study Site - Philadelphia
  • Study Site - Pittsburgh

Alabama

  • Study Site - Birmingham

District of Columbia

  • Study Site - Washington D.C.

Georgia

  • Study Site - Augusta

Illinois

  • Study Site - Chicago

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2002-02
Est. Completion 2004-01
Phase Phase 2
Icagen

4 total trials

What the finished NCT00040677 record still lists

NCT00040677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (69% lower).

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00040677 lists 19 locations in 15 states (California, New York, North Carolina).

Frequently Asked Questions

What is clinical trial NCT00040677 about?

NCT00040677 is a clinical study titled "A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.". ICA-17043 is being developed for the chronic treatment of patients with sickle cell disease (SCD) in both adults and children. ICA-17043 is a potent and specific inhibitor of a channel in human red blood cells (RBCs) that blocks RBC dehydration. ICA-17043 is expected to inhibit RBC dehydration and t...

What is the current status of trial NCT00040677?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2002-02. Estimated completion is 2004-01.

What conditions does trial NCT00040677 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia.

What interventions are being tested in trial NCT00040677?

The interventions under investigation include: Placebo (DRUG), Low Dose ICA-17043 (DRUG), High dose ICA-17043 (DRUG).

Who is sponsoring clinical trial NCT00040677?

This trial is sponsored by Icagen, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00040677 being conducted?

This trial has 19 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00040677's enrollment target sits among peer trials

90 71st of 213 higher than 141 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00040677, the US trial registry maintained by the National Library of Medicine. NCT00040677 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.